Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that it has established a licensing and commercialization agreement with a strategic business partner (“the partner”) in Vietnam for its Denosumab biosimilar products MAILISHU (Prolia® biosimilar) and MAIWEIJIAN (Xgeva® biosimilar). Under the agreement, the partner is responsible for registration and sales of the products in Vietnam, while Mabwell is responsible for the development, production and commercial supply of the products.

Driven by accelerating aging demographics, expanding health insurance coverage, and growing health awareness, demand for biologics and high-end generics in Vietnam continues to rise. In terms of the pharmaceutical market, Vietnam's market size was valued at around USD 8.0 billion in 2025, with a projected CAGR of 6.98%, potentially exceeding USD 14.6 billion by 2034. Vietnam has a population of over 1 million. Among that, 16.1 million residents aged 60 and above, accounting for about 16% of the total population, and is expected to officially enter an aging society by 2038. Vietnam is emerging as a strategic market of growing interest to global pharmaceutical companies.

Mr. Huiguo Hu, Board Member, Senior Vice President and Board Secretary of Mabwell, said, "Vietnam is one of the fastest-growing pharmaceutical markets in Southeast Asia. This partnership marks another significant step forward for us in the Southeast Asian market. We look forward to leveraging our partner's extensive local registration experience and commercialization resources to further enhance the accessibility of high-quality biologics in Vietnam, benefiting more patients locally."